Abrocitinib and Sparsentan: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abrocitinib
Sparsentan
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed abrocitinib (Cibinqo) for eczema and sparsentan (Filspari) for a kidney condition. Here's the concern in plain terms: sparsentan can speed up the liver enzymes that break down abrocitinib. When your body clears abrocitinib faster, there may be less of it around to work, so your eczema might not be controlled as well as expected.
The good news is this is a theoretical concern, meaning it's based on how these drugs behave rather than lots of real-world reports. Keep taking both exactly as prescribed, and let your care team know if your skin symptoms flare up. They can watch how well things are working and adjust your dose if needed.
Effect: Sparsentan is an inducer of CYP2C9 and CYP2C19. Abrocitinib is partly metabolized by these enzymes, so co-administration may increase abrocitinib clearance, lowering its exposure (AUC/Cmax) and potentially reducing efficacy for atopic dermatitis.
- Direction: Reduced abrocitinib effect (enzyme induction, not inhibition; neither is a relevant prodrug here).
- Onset: Unspecified; enzyme induction is typically delayed (days to weeks).
- Evidence: Theoretical.
- Management: Monitor clinical response (disease control). The abrocitinib dose may be individualized and adjusted by the care team if efficacy declines.
What happens
Reduced CYP2C19/CYP2C9 substrate exposure and reduced efficacy of CYP2C19/CYP2C9 substrate
Interaction Deep Dive
When sparsentan, which induces both CYP2C9 and CYP2C19, is given together with medications that act as substrates for CYP2C9 and CYP2C19, the exposure to those substrates may decrease, potentially lowering their effectiveness. Watch for the efficacy of these substrates and adjust the dose if needed1.
Why it happens (mechanism)
Induction of CYP2C9-substrate metabolism by sparsentan; induction of CYP2C19-substrate metabolism by sparsentan
How to manage this interaction
This interaction can be managed. Sparsentan may lower the effect of abrocitinib, so the focus is on making sure your eczema treatment keeps working.
- Keep taking both medications as prescribed unless your prescriber tells you otherwise.
- Your team may monitor how well the abrocitinib is controlling your symptoms.
- If needed, the abrocitinib dose may be adjusted and individualized by your care team.
- Tell your pharmacist or doctor if your skin symptoms return or worsen (more itching, redness, or flare-ups).
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abrocitinib and Sparsentan together?
Sparsentan may reduce how well abrocitinib works by clearing it faster, so keep taking both as prescribed and let your care team know if your eczema flares so they can adjust the dose if needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abrocitinib and Sparsentan interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abrocitinib and Sparsentan interaction managed?
This interaction can be managed. Sparsentan may lower the effect of abrocitinib, so the focus is on making sure your eczema treatment keeps working. Keep taking both medications as prescribed unless your prescriber tells you otherwise. Your team may monitor how well the abrocitinib is controlling your symptoms. If needed, the abrocitinib dose may be adjusted and individualized by your care team. T… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abrocitinib or Sparsentan need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: FILSPARI® oral tablets, sparsentan oral tablets. Travere Therapeutics Inc, San Diego, CA, 2026. DailyMed
Keep reading about Abrocitinib
Keep reading about Sparsentan
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist